Credit Suisse Assumes, Downgrades Esperion Therapeutics (ESPR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Esperion Therapeutics (ESPR) a Top Pick at UBS Into 2nd-Half; Buy on Weakness
June 24, 2015 8:49 AM EDTUBS analyst Andrew Peters is reiterating a Buy rating and $140 price target on Esperion Therapeutics (NASDAQ: ESPR) while naming it a top pick heading into the 2nd-half. The firm views the recent pullback as an opportunity ahead of meaningful near-term catalysts.
"Notably our... More
Esperion Therapeutics (ESPR) Reconfirmed Timelines for Upcoming Catalysts, JMP Securities Notes
June 24, 2015 8:40 AM EDTJMP Securities reiterated a Market Outperform rating and $177 price target on Esperion Therapeutics (NASDAQ: ESPR) after CEO Tim Mayleben reconfirmed timelines for upcoming catalysts.
The analyst highlighted:
The 014 study results are expected in the second half of next month, an... More